GuidelineClinical pharmacology and therapeutics2014
Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 update.
Guideline in Clinical pharmacology and therapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Genetic testing for prevention of severe drug-induced skin rash.The Cochrane database of systematic reviews · 2019Pooled it
- Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update.Clinical pharmacology and therapeutics · 2018Guideline
- Efficacy of personal pharmacogenomic testing as an educational tool in the pharmacy curriculum: A nonblinded, randomized controlled trial.Clinical and translational science · 2021Trial
- Like father, like daughter: amoxicillin-induced aseptic meningitis in a female patient and her father: a case report.Journal of medical case reports · 2026Article
- Review
- Introduction to Pharmacogenomics: Role of the Histocompatibility and Immunogenetics Laboratory in Personalised Medicine-Current Status and Future Prospects.International journal of immunogenetics · 2026Review
- The Burden of Adverse Drug Reactions in Africa in the Context of Pharmacogenetics-Based Clinical Guidelines.Clinical pharmacology and therapeutics · 2026Article
- The cutaneous mirror: leveraging drug-induced skin phenotypes as early visual risk signals for systemic toxicity, a comprehensive review.Frontiers in drug safety and regulation · 2026Review
- Article
- Pharmacotherapy Risks in Rare Genetic Diseases: Cross-Referencing ACMG Secondary Findings v3.2 List With Clinical Databases.Clinical and translational science · 2026Article
- Human leukocyte antigen pharmacogenetics in infectious diseases: anti-infective drug toxicity and host immune response.Frontiers in pharmacology · 2026Review
- Beyond histocompatibility: human leukocyte antigen as a cross-disciplinary platform for immune recognition and clinical decision-making.Frontiers in immunology · 2026Review
- HLA allele profiling and association in Thai patients with confirmed beta-lactam hypersensitivity: an NGS-based analysis.Frontiers in pharmacology · 2026Article
- Use of Drugs With Actionable Pharmacogenetic Biomarkers and Possible Prescribing Changes Among Older People.Journal of the American Geriatrics Society · 2025Article
- Genome-wide screening of pharmacogenomic biomarkers in jordanian patients with genetic disorders.The pharmacogenomics journal · 2025Article
- Gaps in guideline adherence: evaluating HLA-B*57:01 screening for abacavir sensitivity and the implementation of evidence-based HIV care.Clinical biochemistry · 2025Article
- Improved Pharmacogenomic Testing Process for Veterans in Outpatient Settings by Clinical Pharmacist Practitioners.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2025Article
- Vancomycin Drug Reaction with Eosinophilia and Systemic Symptoms: Meta-Analysis and Pharmacovigilance Study.Journal of clinical medicine · 2025Review
- Pharmacogenetics: Opportunities for theAnnual review of pharmacology and toxicology · 2025Review
- Patterns of pharmacogenetic variation in nine biogeographic groups.Clinical and translational science · 2024Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
The Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for HLA-B Genotype and Abacavir Dosing were originally published in April 2012. We reviewed recent literature and concluded that none of the evidence would change the therapeutic recommendations in the original guideline; therefore, the original publication remains clinically current. However, we have updated the Supplementary Material online and included additional resources for applying CPIC guidelines to the electronic health record. Up-to-date information can be found at PharmGKB (http://www.pharmgkb.org).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.